Q1 Earnings Estimate for Ovid Therapeutics Issued By Wedbush

Ovid Therapeutics Inc. (NASDAQ:OVID) – Stock analysts at Wedbush issued their Q1 2026 earnings per share estimates for shares of Ovid Therapeutics in a report released on Tuesday, May 13th. Wedbush analyst L. Chico anticipates that the company will earn ($0.15) per share for the quarter. Wedbush has a “Outperform” rating and a $3.00 price objective on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. Wedbush also issued estimates for Ovid Therapeutics’ Q2 2026 earnings at ($0.15) EPS.

Ovid Therapeutics (NASDAQ:OVID) last issued its earnings results on Tuesday, May 13th. The company reported ($0.14) earnings per share for the quarter, hitting the consensus estimate of ($0.14). Ovid Therapeutics had a negative return on equity of 39.24% and a negative net margin of 5,142.56%. The company had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.03 million.

OVID has been the topic of several other reports. Oppenheimer raised Ovid Therapeutics from a “market perform” rating to an “outperform” rating and set a $4.00 target price on the stock in a research report on Wednesday, January 29th. BTIG Research decreased their price target on Ovid Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research note on Monday, March 24th. Finally, William Blair upgraded Ovid Therapeutics to a “strong-buy” rating in a research note on Thursday, April 24th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Ovid Therapeutics has an average rating of “Buy” and an average price target of $3.03.

Ovid Therapeutics Stock Performance

Shares of OVID stock opened at $0.31 on Thursday. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.66 and a quick ratio of 5.66. Ovid Therapeutics has a fifty-two week low of $0.24 and a fifty-two week high of $3.41. The stock’s 50-day moving average is $0.34 and its two-hundred day moving average is $0.70. The firm has a market cap of $21.71 million, a P/E ratio of -0.65 and a beta of 0.27.

Institutional Trading of Ovid Therapeutics

Several hedge funds have recently added to or reduced their stakes in OVID. XTX Topco Ltd bought a new stake in Ovid Therapeutics during the 1st quarter valued at approximately $29,000. SG Americas Securities LLC boosted its stake in Ovid Therapeutics by 83.9% during the 4th quarter. SG Americas Securities LLC now owns 37,636 shares of the company’s stock valued at $35,000 after purchasing an additional 17,172 shares during the period. Nuveen LLC bought a new stake in Ovid Therapeutics during the 1st quarter valued at approximately $37,000. Bank of America Corp DE boosted its stake in Ovid Therapeutics by 49.7% during the 4th quarter. Bank of America Corp DE now owns 56,733 shares of the company’s stock valued at $53,000 after purchasing an additional 18,841 shares during the period. Finally, Velan Capital Investment Management LP bought a new stake in Ovid Therapeutics during the 4th quarter valued at approximately $65,000. Institutional investors own 72.24% of the company’s stock.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.